10 - 12 MAY GENEVA, PALEXPO
lt's been almost 10 years since the last new synthesis path for Menaquinone-7 has been commercialised. The wait was undoubtedly worthwhile.
Now VitaSynth is challenging the market with its second-generation synthesis technology. Capitalising on our 12 years of experience in manufacturing and elementary research, we proudly bring in Pharmoquinone® range of Vitamin K2 actives and dilutions.
Our purity is supported by advanced analytics both for API and dilutions. Our UPLC method surpasses the old USP method (HPLC) in accuracy and selectivity. Our technicians can see more peaks as the actual assay - purity of a sample is always lower than reported by the USP method.
Our capacity in 2021 ranges between 30-50% of current global synthetic K2 sales. In April we have doubled our production space in Warsaw. New production rooms are now being adopted.
The largest K2 brands sold by pharmacists do not use “natural origin” narration in their marketing materials, however, there are still companies trying to persuade end-users to pay premium for “natural” K2, suggesting increased safety or absorption.
“All-trans vitamin K2” does not exist. The isomerisation of Mk-7 and Mk-6 takes place on every step of processing (drying, dilution, tabletting, encapsulation, storage) regardless of “natural” or “synthetic” origin.
“Natural vitamin K2” is a fully artificial product, designed by people and not existing in the nature. Nor the modified bacteria strain neither their growth medium exist in nature. The process is fully artificial ("man-made").
Our logistics are independent of supply from India and China as we have the capacity to effect 100% of the process in-house.
All production steps are performed in-house
All oil and powder dilutions are made in-house
Air and truck shipments are insured for 100% value
Stable stock of Active Ingredient in cold storage
Average global delivery time is 7-10 days (door to door)